Roche reports Q1 group sales CHF 14.7B vs. CHF 15.4B last year

In the first three months of 2026, Roche (RHHBY) sales were +6% at CER, -5% when reported in CHF, to CHF 14.7B due to strong demand for pharmaceutical products and diagnostic solutions. The appreciation of the Swiss franc against most currencies, notably the US dollar, had a significant impact on the results reported in Swiss francs compared to constant exchange rates. Roche CEO Thomas Schinecker: “We delivered a strong start to the year, achieving 6% Group sales growth at constant exchange rates. Our pipeline continued to advance in areas where patients face significant unmet need, including multiple sclerosis, obesity and a severe autoimmune disease that can lead to kidney failure. We also received EU approval for a new test to detect neuroinflammation in multiple sclerosis, marking a meaningful step forward in disease management. Our diversified portfolio across both divisions, together with continued pipeline progress, positions us well for sustained future growth in a dynamic geopolitical environment. We confirm our full-year outlook.”